Vaxcyte (PCVX) Stock Forecast, Price Target & Predictions


OverviewRevenueOwnershipFinancialsChartTranscripts

PCVX Stock Forecast


Vaxcyte stock forecast is as follows: an average price target of $124.14 (represents a 16.57% upside from PCVX’s last price of $106.49) and a rating consensus of 'Buy', based on 8 wall street analysts offering a 1-year stock forecast.

PCVX Price Target


The average price target for Vaxcyte (PCVX) is $124.14 based on 1-year price targets from 8 Wall Street analysts in the past 3 months, with a price target range of $163.00 to $58.00. This represents a potential 16.57% upside from PCVX's last price of $106.49.

PCVX Analyst Ratings


Buy

According to 8 Wall Street analysts, Vaxcyte's rating consensus is 'Buy'. The analyst rating breakdown for PCVX stock is 0 'Strong Buy' (0.00%), 8 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Vaxcyte Price Target by Analyst


DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Sep 10, 2024Salim SyedMizuho Securities$163.00$115.2841.39%53.07%
Sep 04, 2024Jason GerberryBank of America Securities$140.00$110.1527.10%31.47%
Sep 03, 2024David RisingerLeerink Partners$153.00$112.0436.56%43.68%
Sep 03, 2024Tom ShraderBTIG$160.00$110.1545.26%50.25%
Sep 03, 2024Roger SongJefferies$129.00$111.1316.09%21.14%
Sep 03, 2024Salim SyedMizuho Securities$113.00$111.081.72%6.11%
Aug 07, 2024Tom ShraderBTIG$98.00$70.5238.97%-7.97%
Jan 03, 2023-Needham$58.00$47.9520.96%-45.53%
Dec 16, 2022-Leerink Partners$60.00$45.4831.93%-43.66%
Dec 15, 2022-Guggenheim$66.00$45.7244.36%-38.02%
Row per page
Go to

The latest Vaxcyte stock forecast, released on Sep 10, 2024 by Salim Syed from Mizuho Securities, set a price target of $163.00, which represents a 41.39% increase from the stock price at the time of the forecast ($115.28), and a 53.07% increase from PCVX last price ($106.49).

Vaxcyte Price Target by Period


1M3M12M
# Anlaysts-77
Avg Price Target-$136.57$136.57
Last Closing Price$106.49$106.49$106.49
Upside/Downside-100.00%28.25%28.25%

In the current month, the average price target of Vaxcyte stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Vaxcyte's last price of $106.49. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades


DateCompanyPrevious RatingNew RatingRating Change
Sep 04, 2024GuggenheimBuyBuyHold
Sep 03, 2024Cowen & Co.BuyBuyHold
Sep 03, 2024NeedhamBuyBuyHold
Sep 03, 2024BTIGBuyBuyHold
Sep 03, 2024JefferiesBuyBuyHold
Aug 07, 2024BTIGBuyBuyHold
Mar 12, 2024Morgan StanleyBuyBuyHold
Mar 12, 2024WedbushBuyBuyHold
Jan 03, 2023NeedhamBuyBuyHold
Dec 16, 2022SVB Leerink-OutperformInitialise
Row per page
Go to

Vaxcyte's last stock rating was published by Guggenheim on Sep 04, 2024. The company gave PCVX a "Buy" rating, the same as its previous rate.

Vaxcyte Financial Forecast


Vaxcyte Revenue Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Jun 20
Revenue--------
Avg Forecast-------$166.67K
High Forecast-------$166.67K
Low Forecast-------$166.67K
# Analysts-------1
Surprise %--------

Vaxcyte's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. PCVX's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).

Vaxcyte EBITDA Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Jun 20
# Analysts-------1
EBITDA-------$-19.96M
Avg Forecast-------$-12.81M
High Forecast-------$-10.24M
Low Forecast-------$-15.37M
Surprise %-------1.56%

undefined analysts predict PCVX's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Vaxcyte's previous annual EBITDA (undefined) of $NaN.

Vaxcyte Net Income Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Jun 20
# Analysts-------1
Net Income-------$-20.32M
Avg Forecast$-164.16M$-158.30M$-158.30M$-152.43M$-136.89M$-129.08M$-114.39M$-13.12M
High Forecast$-164.16M$-158.30M$-158.30M$-152.43M$-136.89M$-115.91M$-114.39M$-10.50M
Low Forecast$-164.16M$-158.30M$-158.30M$-152.43M$-136.89M$-143.57M$-114.39M$-15.74M
Surprise %-------1.55%

Vaxcyte's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. PCVX's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).

Vaxcyte SG&A Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Jun 20
# Analysts-------1
SG&A-------$2.01M
Avg Forecast--------
High Forecast--------
Low Forecast--------
Surprise %--------

Vaxcyte's average Quarter SG&A projection for Jun 24 is -, based on 0 Wall Street analysts, with a range of - to -. The forecast indicates a -100.00% fall compared to PCVX last annual SG&A of $2.01M (Jun 20).

Vaxcyte EPS Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Jun 20
# Analysts-------1
EPS-------$-1.72
Avg Forecast$-1.40$-1.35$-1.35$-1.30$-1.17$-1.10$-0.98$-1.27
High Forecast$-1.40$-1.35$-1.35$-1.30$-1.17$-0.99$-0.98$-1.27
Low Forecast$-1.40$-1.35$-1.35$-1.30$-1.17$-1.22$-0.98$-1.27
Surprise %-------1.36%

According to undefined Wall Street analysts, Vaxcyte's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to PCVX previous annual EPS of $NaN (undefined).

Vaxcyte Peer Comparison by Price Target


TickerCompanyLast Closing PriceAvg Price TargetUpside/DownsideAvg Rating
VTYXVentyx Biosciences$2.15$33.861474.88%Buy
STROSutro Biopharma$3.69$11.14201.90%Buy
LRMRLarimar Therapeutics$7.57$20.33168.56%Buy
APLSApellis Pharmaceuticals$28.56$76.13166.56%Buy
IMCRImmunocore$31.17$70.75126.98%Buy
SNDXSyndax Pharmaceuticals$18.94$36.1190.65%Buy
LEGNLegend Biotech$43.61$82.6289.45%Buy
VRDNViridian Therapeutics$22.84$37.8365.63%Buy
LQDALiquidia$10.46$17.1764.15%Buy
BMRNBioMarin Pharmaceutical$66.01$101.7054.07%Buy
MRUSMerus$51.23$77.1350.56%Buy
AKROAkero Therapeutics$32.05$46.0043.53%Buy
DICEDICE Therapeutics$47.55$60.0026.18%Buy
TECHBio-Techne$75.90$91.6920.80%Buy
NUVLNuvalent$89.53$107.8320.44%Buy
TVTXTravere Therapeutics$18.10$21.3818.12%Buy
PCVXVaxcyte$106.49$124.1416.57%Buy
ACLXArcellx$86.44$71.57-17.20%Buy

PCVX Forecast FAQ


Yes, according to 8 Wall Street analysts, Vaxcyte (PCVX) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 8 'Buy' recommendations, accounting for 100.00% of PCVX's total ratings.

Vaxcyte (PCVX) average price target is $124.14 with a range of $58 to $163, implying a 16.57% from its last price of $106.49. The data is based on 8 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

According to Wall Street analysts' prediction for PCVX stock, the company can go up by 16.57% (from the last price of $106.49 to the average price target of $124.14), up by 53.07% based on the highest stock price target, and down by -45.53% based on the lowest stock price target.

PCVX's average twelve months analyst stock price target of $124.14 does not support the claim that Vaxcyte can reach $200 in the near future.

Vaxcyte's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-380M (high $-367M, low $-395M), average SG&A $0 (high $0, low $0), and average EPS is $-3.244 (high $-3.131, low $-3.367). PCVX's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-633M (high $-633M, low $-633M), average SG&A $0 (high $0, low $0), and average EPS is $-5.4 (high $-5.4, low $-5.4).